Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.

Alexandra M NanzerMichael E WechslerDaniel J JacksonDavid BernsteinStephanie KornPaul E PfefferRuchong ChenJunpei SaitoGustavo de Luíz MartinezLucyna DymekLoretta JacquesNicholas BirdStein SchalkwijkDouglas SmithPeter HowarthIan D Pavordnull null

Published in: The New England journal of medicine (2024)

Depemokimab reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype. (Funded by GSK; SWIFT-1 and SWIFT-2 ClinicalTrials.gov numbers, NCT04719832 and NCT04718103.).

Keyphrases

chronic rhinosinusitis
chronic obstructive pulmonary disease
cystic fibrosis
signaling pathway
pi k akt